In 2020, the second batch of plant extract group standards was approved
On October 14, the China Chamber of Commerce for Import and Export of Medicines and Health Products approved the establishment of the second batch of 5 plant extract group standards in 2020, and it is hereby announced. The project list is as follows:
Cassia Seed Extract
Glucosyl steviol glycoside
Yunzhi Extract
Echinacea Extract
Inonotus obliquus extract
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea Tests Arctic Commercial Route as Asian Exporters Seek New Logistics Alternatives
-
Hormuz Traffic Remains 90% Below Pre-Conflict Levels as Limited Tanker Access Offers Partial Relief
-
Korea’s First Petrochemical Restructuring Approved, LDPE Market Concentration Surges to 82%
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
Nestlé Drops Artificial Colors Worldwide by 2026: Food Additives Face a Reformulation Shock
-
U.S. Includes Lithium in National Defense Stockpile for First Time, Plans to Purchase 16,200 Tons Over Five Years
-
BASF's Zhanjiang Integrated Site Reaches Major Milestone: Butyl Acrylate Production Commences Ahead of Schedule, Steam Cracker Completes Mechanical Completion
-
Geno and Sojitz Collaborate to Accelerate the Commercialization of Nylon 6
-
European Petrochemical Weakness Leaves Naphtha Oversupplied as Cracker Demand Struggles
-
A Faster Route to Diabetes Drug Chemistry
Recommend Reading
-
Wanhua Chemical’s 2025 Revenue Exceeds RMB 200 Billion While Net Profit Remains Under Pressure
-
Nestlé Drops Artificial Colors Worldwide
-
EU Clears a New Gut Health Ingredient
-
Carrot Extract Gets EU Novel Food Approval
-
Probiotics Push for Economic Value
-
Since December, China’s phenol market has accelerated its downward trend and is now fluctuating at low levels
-
MTBE Market Conditions Remain Weak
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
After Two Rounds of Price Cuts, the Coke Market Stabilizes in China
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger